A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

Abstract Background This trial explores SM‐88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) Methods Forty‐nine patients were randomized to daily 460 or 920 mg oral SM‐88 with MPS (SM‐88 Regimen). The primary endpoint was objec...

Full description

Bibliographic Details
Main Authors: Marcus S. Noel, Semmie Kim, Marion L. Hartley, Steve Wong, Vincent J. Picozzi, Harry Staszewski, Dae Won Kim, Jan M. Van Tornout, Philip Agop Philip, Vincent Chung, Allyson J. Ocean, Andrea Wang‐Gillam
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.4768

Internet

https://doi.org/10.1002/cam4.4768

Similar Items